Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)

China flag China · Delayed Price · Currency is CNY
6.13
+0.20 (3.37%)
Apr 29, 2026, 3:04 PM CST
23.59%
Market Cap 3.85B
Revenue (ttm) 669.64M
Net Income (ttm) -130.94M
Shares Out 627.62M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 18,733,433
Average Volume 36,871,686
Open 6.18
Previous Close 5.93
Day's Range 6.04 - 6.20
52-Week Range 4.90 - 10.07
Beta 0.64
RSI 43.58
Earnings Date Apr 29, 2026

About SHE:300639

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/i... [Read more]

Sector Healthcare
Founded 2003
Employees 2,205
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300639
Full Company Profile

Financial Performance

In 2025, SHE:300639's revenue was 669.64 million, a decrease of -17.89% compared to the previous year's 815.53 million. Losses were -130.94 million, -80.01% less than in 2024.

Financial Statements

News

There is no news available yet.